BioSpace News Archive

IDEAYA Biosciences, Inc. announced the pricing of an underwritten public offering of common stock and pre-funded warrants.

Santhera Pharmaceuticals and ReveraGen BioPharma, Inc announce the successful completion of the mid-cycle review meeting by the U.S. Food and Drug Administration of the new drug application for vamorolone for the treatment of Duchenne muscular dystrophy.

OKYO Pharma Limited announces the activation of the first clinical trial site in the U.S. for its phase 2, multi-center, randomized, double-blinded, placebo-controlled trial, evaluating the efficacy and safety of OK-101 ophthalmic solution in subjects with dry eye disease.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

Neteera Technologies Ltd., an Israeli-based startup disrupting the patient monitoring market, announced the successful closing of a ~$13M Series B funding round.

AMO Pharma Limited announced completion of treatment for the final patient enrolled in the company’s REACH-CDM clinical study of the investigational therapy AMO-02.

Danaher Corporation announced results for the first quarter 2023. Net earnings refer to net earnings attributable to common shareholders.

GE HealthCare, a leading global precision care innovator, reported financial results for the first quarter ended March 31, 2023.

Asensus Surgical, Inc. today announced that Fukuoka Tokushukai Hospital in Kasuga City, Japan has entered into an agreement to lease and utilize a Senhance® Surgical System.

PureTech Health plc noted today that its Founded Entity, Vedanta Biosciences today announced that it has raised $106.5 million to support pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a Phase 2 study of VE202 for ulcerative colitis, among other development activities.